tiprankstipranks
Cytokinetics presents new data at American Heart Association sessions
The Fly

Cytokinetics presents new data at American Heart Association sessions

Cytokinetics announced new data from two additional analyses from GALACTIC-HF, as well as an analysis of patients hospitalized for heart failure with reduced ejection fraction from the Get With The Guidelines-Heart Failure Registry, were presented at the American Heart Association Scientific Sessions 2022 in Chicago, IL. Reduction in Heart Failure Events for North American Patients Treated with Omecamtiv Mecarbil in GALACTIC-HF Associated with 26.9% Cost Reduction over Three Years: Nihar Desai presented data from an analysis of the healthcare resource use, early benefit and costs of hospitalization for North American patients with heart failure with reduced ejection fraction treated with omecamtiv mecarbil in GALACTIC-HF. This analysis included 1,090 North American patients from GALACTIC-HF matching the criteria of a subgroup of patients previously identified as being the most likely to benefit from treatment with omecamtiv mecarbil. In this subgroup, treatment with omecamtiv mecarbil was associated with a reduction in the risk of the primary composite endpoint of cardiovascular death or first heart failure event and a reduction in the risk of first heart failure event. The estimated cost reduction due to heart failure events avoided with omecamtiv mecarbil averaged $420 per patient at 30 days, $928 per patient at 90 days, and $6,052 per patient at 3 years, suggesting that treatment with omecamtiv mecarbil is associated with both a clinical and economic benefit for patients with HFrEF. Women Enrolled in GALACTIC-HF Had Lower Quality of Life at Baseline and Lower Rate of the Primary Outcome; Treatment Benefit from Omecamtiv Mecarbil Did Not Differ from Men: Maria Pabon Porras presented data from an analysis from GALACTIC-HF on sex differences in baseline characteristics, clinical outcomes, efficacy and safety of omecamtiv mecarbil. Of 8,232 patients enrolled, 1,749 were women. At baseline, women had lower Kansas City Cardiomyopathy Questionnaire scores, indicating they had worse quality of life, and they were less likely to be treated with guideline recommended medical therapies and devices than men. For both men and women, KCCQ scores at baseline were highly predictive of incidence rates of the primary outcome, however, compared to men, women had a 20% lower adjusted risk of the primary composite endpoint, and had lower rates of serious adverse events than men. The treatment effect of omecamtiv mecarbil did not differ between men and women.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on CYTK:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles